AbbVie recently announced positive top-line results from its Phase 3 Select-Next trial, which evaluated upadacitinib as a treatment for rheumatoid arthritis patients. Read More »
Ardsley, New York-based biopharmaceutical firm Acorda Therapeutics revealed new information derived from clinical and preclinical studies of tozadenant at the recent 2017 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Vancouver, British Columbia. Read More »
Commencing a Phase 3b trial of daily oral medication ALKS 5461, Alkermes PLC will assess the treatment’s feasibility and safety for major depressive disorder patients with insufficient prior results obtained from other drugs. Read More »
Astellas, a global pharmaceutical corporation with U.S. headquarters in Northbrook, Illinois, and biotechnology company Seattle Genetics recently publicized findings on their enfortumab vedotin (ASG-22ME) treatment for a type of cancer commonly manifesting in the bladder. Read More »
ReachBio Research Labs recently announced that it launched cellPrism, a drug development platform designed to deliver a spectrum of customized in-vitro assays to biotechnology and pharmaceutical companies. Read More »
OneOme, the company behind the OneOme RightMed pharmacogenomics test, recently delivered a statement about how DNA has the power to minimize medication trial and error and help people with heart conditions improve their cardiovascular treatments. Read More »
The American Pharmacists Association (APA) recently announced that new research shows adding 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy led to an increase in survival rates and for patients with recurrent prostate cancer. Read More »
Amgen's Fourier trial for Repatha met its primary composite endpoint and the key secondary composite endpoint. Read More »
The U.S. Supreme Court issued a 9-0 ruling today that will have the effect of speeding the process for biosimilars going to market. Read More »
The Texas Pharmacy Association (TPA) has received a grant from the Community Pharmacy Foundation and Texas Department of State Health Services that will allow the association to create community-based health care provider digital linkages with pharmacists. Read More »
Fortified with time-release traits, Egalet Corp.’s Guardian tablet has received a U.S. patent, enabling the Pennsylvania-based firm to adapt the medication for potential future products. Read More »
Pfizer Inc. and Celltrion Healthcare presented data at the 12th Congress of the European Chron’s and Colitis Organisation showing Inflectra (infliximab CT-P13) delivers similar efficacy and safety as Remicade (infliximab) for treating Chron’s Disease. Read More »
Sanofi and Regeneron Pharmaceuticals Inc. recently shared the results of a Phase 3 Chronos study as a late-breaking abstract at the annual meeting of the American Academy of Dermatology. Read More »
Portola Pharmaceuticals Inc. presented data from its pivotal Phase 3 APEX study for the investigational drug betrixaban at a poster session at the American College of Cardiology’s 66th Annual Scientific Session & Expo. Read More »
Sanofi and Regeneron Pharmaceuticals Inc. recently presented Phase 3 clinical trial data and multiple additional analyses from the Praluent (alirocumab) Injection's Odyssey clinical trial program at the American College of Cardiology Scientific Sessions in Washington, D.C. Read More »
Biohaven Pharmaceutical Holding Company Ltd. has finished its enrollment in the clinical study for trigriluzole for individuals with spinocerebellar ataxia, a rare neurodegenerative disorder. Read More »
AM-Pharma B.V. has finished recruiting for its Phase II trial of treatment for individuals with Acute Kidney Injury. Read More »
TapImmune Inc. has completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, which is a multi-epitope T-cell vaccine developed by the company that targets the folate receptor alpha. Read More »
A new Glaukos Corporation study reveals that the cost of two iStent Trabecular Micro-Bypass Stents could cost lower cumulatively in five years compared to others like the selective laster trabeculoplasty (also known as the SLT) or topical glaucoma medication. Read More »
NovellusDx has been given a new patent by the name of "Methods and Systems for Identifying Patient Specific Driver Mutations." Read More »
Alerts Sign-up
